Targeted agents are certainly effective in lymphoma, especially CD20 monoclonal antibody, also called rituximab, which has changed the clinical efficacy of non-Hodgkin’s lymphoma, improved the objective remission rate, prolonged the overall survival time of patients, and can be considered as very good and effective drugs. It is very suitable for non-Hodgkin’s lymphoma with CD20 overexpression, such as follicular lymphoma, set cell lymphoma, and diffuse large B-cell lymphoma, so the targeted drugs are very effective for lymphoma. Newer targeted drugs, such as immune checkpoint inhibitors like PD-1 or PD-L1, are also targeted drugs and are also very effective in refractory, relapsed Hodgkin’s lymphoma.